FinnCap reiterated their corporate rating on shares of Cambridge Cognition (LON:COG) in a report issued on Monday, ThisIsMoney.Co.Uk reports.
Shares of COG stock opened at GBX 62 ($0.81) on Monday. The stock’s 50-day moving average is GBX 62.69 and its two-hundred day moving average is GBX 71.03. The firm has a market cap of $14.99 million and a price-to-earnings ratio of -8.86. Cambridge Cognition has a 1 year low of GBX 55 ($0.72) and a 1 year high of GBX 152 ($1.99).
About Cambridge Cognition
Cambridge Cognition Holdings Plc, a neuroscience technology company, develops digital health products. The company offers CANTAB Recruit, an online patient recruitment platform for pharmaceutical and biotechnology companies to identify qualified clinical trial participants in high-need indications, such as Alzheimer's disease; CANTAB Connect that provides digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas from phases IIV or a cognitive testing software that enhances the chances of success and minimizing the risk of failure in neuroscience research; and Cognition Kit, a digital health platform, which delivers wearable and smartphone apps to provide engaging digital health solutions for the enhancement of patient engagement, demonstration of treatment efficacy, and understanding of a disease and a patient's response to medication.
Further Reading: When can a hold rating present a buying opportunity?
Receive News & Ratings for Cambridge Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambridge Cognition and related companies with MarketBeat.com's FREE daily email newsletter.